JC03 Rec'd PCT/PTO 0 2 MAY 2004

ORM PTO-1390 (Modified) U.S. PATENT AND TRADEMARK OFFICE; U.S. DEPARTMENT OF COMMERCE REV. 2-2005) **PU5025USW** TRANSMITTAL LETTER TO THE UNITED STATES U.S. APPLICATION NO. (If known, see 37 CFR 1.5) DESIGNATED/ELECTED OFFICE (DO/EO/US) 10/533325 CONCERNING A SUBMISSION UNDER 35 U.S.C. 371 PRIORITY DATE CLAIMED INTERNATIONAL APPLICATION NO. INTERNATIONAL FILING DATE PCT/US03/035830 November 7, 2003 November 8, 2002 TITLE OF INVENTION Pharmaceutical Antiviral Compositions APPLICANT(S) FOR DO/EO/US GOODSON, Gary, Wayne; FLOYD, Alison, Green; NAVY, Cecillia, Carpenter Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information: This is a FIRST submission of items concerning a submission under 35 U.S.C. 371. This is a SECOND or SUBSEQUENT submission of items concerning a submission under 35 U.S.C. 371. 2. 3. This is an express request to begin national examination procedures (35 U.S.C. 371(f)). The submission must include items (5), (6), (9) and (24) indicated below. The US has been elected (Article 31). 4. 5. A copy of the International Application as filed (35 U.S.C. 371 (c)(2)) is attached hereto (required only if not communicated by the International Bureau). b. 🗆 has been communicated by the International Bureau. is not required, as the application was filed in the United States Receiving Office (RO/US). An English language translation of the International Application as filed (35 U.S.C. 371(c)(2)). a. 🗆 is attached hereto. b. 🗆 has been previously submitted under 35 U.S.C. 154(d)(4). 7. Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371 (c)(3)) are attached hereto (required only if not communicated by the International Bureau). b. 🗆 have been communicated by the International Bureau. c. 🗆 have not been made; however, the time limit for making such amendments has NOT expired. have not been made and will not be made. An English language translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)). X 9 An oath or declaration of the inventor(s) (35 U.S.C. 371 (c)(4)). 10. An English language translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371 (c)(5)). 11. A copy of the International Preliminary Examination Report (PCT/IPEA/409). 12. A copy of the International Search Report (PCT/ISA/210). Items 13 to 23 below concern document(s) or information included: 13. An Information Disclosure Statement under 37 CFR 1.97 and 1.98. 14. An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included. 15. A FIRST preliminary amendment. 16. A SECOND or SUBSEQUENT preliminary amendment. 17. A substitute specification. 18 A power of attorney and/or change of address letter. 19. A computer-readable form of the sequence listing in accordance with PCT Rule 13ter.2 and 37 CFR 1.821 - 1.825. 20. A second copy of the published International Application under 35 U.S.C. 154(d)(4). 21. A second copy of the English language translation of the International Application under 35 U.S.C. 154(d)(4). 22. \boxtimes Express Mail Label No. EV 332065346 US 23. \boxtimes Other items or information: a) PCT Cover Page

Express Mail Label No EV 332065346 US

b) PCT Request

JC17 Rec'd PCT/PTO 0 2 MAY 2005

PTO-1390 (Rev. 02-2005)
Approved for use through 3/31/2007. OMB 0651-0021
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

U.S. APPLICATION NO (If Known, 500 37 CFR 5) INTERNATIONAL APPLIC			ICATION NO.	ATTORNEY'S DOCKET NUMBER					
	PC1/0303/033830				PU5025USW				
The following	g fees are submitte	ed:				CALCULATIONS	PTO USE		
	ational fee		•••••		\$300	\$ \$300.00			
25. Examination fee If International preliminary examination report prepared by USPTO and all claims satisfy provisions of PCT Article 33(1)-(4). \$100 All other situations. \$200						\$ \$200.00			
Search fee (37 C the USPTO as ar International Sea All other situation	fee	\$ \$400.00 \$ \$900.00							
Additional fee for specification and drawings filed in paper over 100 sheets (excluding sequence listing or computer program listing filed in an electronic medium). The fee is \$250 for each additional 50 sheets of paper or fraction thereof.						İ			
Total Sheets	Extra Sheets	Number o	Number of each additional 50 or raction thereof (round up to a whole						
- 100 =	0 /50 =		0		× \$250.00	\$ \$0.00			
Surcharge of \$130.00 for furnishing the oath or declaration later than months from the earliest claimed priority date (37 CFR 1.492(e)).						\$			
CLAIMS	NUMBER F	ILED N	IUMBER EXTRA		RATE				
Total claims	17	- 20 =	0	x	\$50.00	\$ \$0.00			
Independent clair	ms 3	- 3=	0	х	\$200.00	\$ \$0.00			
MULTIPLE DEPE	ENDENT CLAIMS	(if applicable)		+	\$360.00	\$ \$0.00			
TOTAL OF ABOVE CALCULATIONS =						\$ \$900.00			
	aims small entity st	\$ \$0.00							
reduced by 1	1/2.	\$ \$900.00							
Processing fee of \$130.00 for furnishing the English translation later than 30 months from the earliest claimed priority date (37 CFR 1.492(f)).						\$ \$0.00			
TOTAL NATIONAL FEE =						\$ \$900.00			
Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). \$40 per property +						\$ \$0.00			
TOTAL FEES ENCLOSED =						\$ \$900.00			
						Amount to be	\$		
						Amount to be	\$		
a. 🔲 A check	in the amount of \$		to cover the a	bove	fees is enclosed		1		
b. Please charge my Deposit Account No. 07-1392 in the amount of \$900.00 to cover the above fees. A duplicate copy of this sheet is enclosed.									
c. The Director is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. 07-1392 . A duplicate copy of this sheet is enclosed.									
d. Fees are to be charged to a credit card. WARNING: Information on this form may become public. Credit card									
information should not be included on this form. Provide credit card information and authorization on PTO-2038. NOTE: Where an appropriate time limit under 37 CFR 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b))									
	must be filed and granted to restore the International Application to pending status. SEND ALL CORRESPONDENCE TO:								
SEIND ALL CORP	YESPONDENCE I	K. Mus							
Karen L. 1						_			
23347 Raren L. 1									
					TON NUMBER				

			1/577705
CERTIFICATE OF Applicant(s): Goodson 6	MANG BY "EXPRESS :	MAIL" (37 CFRC1	PCT/PTO 0 MAY 20
Serial No. To Be Assigned	Filing Date Concurrently Herewith	Examiner	Group Art Unit
Invention: Pharmaceut	ical Antiviral Compositions		
: 		,	
	<u> </u>		
I hereby certify that the	e following correspondence:		
Transmittal of Nationa	al Phase Application w/accompany	ying papers	
	(Identify type	of correspondence)	
is being deposited wit	h the United States Postal Servi	ce "Express Mail Post Office to A	ddressee" service under 37
CFR 1.10 in an envelo	ppe addressed to: Commissione	r for Patents, P.O. Box 1450, Alex	xandria, VA 22313-1450 on
\underline{m}	(Bate)		
		Valerie L. Phil	
		(Typed or Printed Name of Person Ma) (Signature of Person Mailing Co	lin
		* FV332065	21171
		Express mun muning zun	v
		, · · · -	